Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Itepekimab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms AERIFY-2
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 25 Jul 2024 According to a Sanofi media release, data for phase 3 expected and regulatory submission in US, EU expected in H2 2025.
- 12 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2024 This trial has been completed in Denmark as per European Clinical Trials Database record.